Why the study?
Semaglutide improves cardiometabolic outcomes in obesity, but its underlying mechanisms remain incompletely understood.
Does semaglutide improve myocardial perfusion, strain, and ectopic lipid accumulation in a mouse model of cardiometabolic heart disease?
Population
Mice fed a high-fat, high-sucrose diet
Comparison
Semaglutide vs pair-fed controls
Design
Preclinical animal study
Key result
Semaglutide reversed ectopic lipid accumulation, impaired myocardial perfusion reserve, and diastolic dysfunction in a mouse model of cardiometabolic heart disease.
Authors
Loading...
Semaglutide improves myocardial parameters independent of weight loss in obese mice; leaves open translation to human cardiometabolic heart disease.
Does semaglutide improve myocardial perfusion, strain, and ectopic lipid accumulation in a mouse model of cardiometabolic heart disease?
Semaglutide reverses key imaging and histological features of obesity-induced cardiometabolic heart disease in mice, independent of weight loss from reduced caloric intake.
Skacel et al. (2026) studied Obesity-induced cardiometabolic heart disease. Semaglutide vs. Pair-fed controls was evaluated on Epicardial adipose tissue volume and composition, myocardial fat fraction, adenosine myocardial perfusion reserve, systolic strain, diastolic function, and myocardial fibrosis. Semaglutide reversed ectopic lipid accumulation, impaired myocardial perfusion reserve, and diastolic dysfunction in a mouse model of cardiometabolic heart disease.